These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 31766255)

  • 1. The Clinicopathological Spectrum of Acromegaly.
    Akirov A; Asa SL; Amer L; Shimon I; Ezzat S
    J Clin Med; 2019 Nov; 8(11):. PubMed ID: 31766255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Update on Pituitary Neuroendocrine Tumors Leading to Acromegaly and Gigantism.
    Asa SL; Ezzat S
    J Clin Med; 2021 May; 10(11):. PubMed ID: 34067494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages.
    Mete O; Alshaikh OM; Cintosun A; Ezzat S; Asa SL
    Endocr Pathol; 2018 Dec; 29(4):332-338. PubMed ID: 30215160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ectopic secretion of growth hormone-releasing hormone (GHRH) in neuroendocrine tumors: relevant clinical aspects.
    Doga M; Bonadonna S; Burattin A; Giustina A
    Ann Oncol; 2001; 12 Suppl 2():S89-94. PubMed ID: 11762359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormone secretion in vitro by plurihormonal pituitary adenomas of the acidophil cell line.
    Asa SL; Kovacs K; Horvath E; Singer W; Smyth HS
    J Clin Endocrinol Metab; 1992 Jul; 75(1):68-75. PubMed ID: 1352308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathophysiology of acromegaly.
    Melmed S; Braunstein GD; Horvath E; Ezrin C; Kovacs K
    Endocr Rev; 1983; 4(3):271-90. PubMed ID: 6354702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth hormone (GH) and prolactin (PRL) gene expression and immunoreactivity in GH- and PRL-producing human pituitary adenomas.
    Li J; Stefaneanu L; Kovacs K; Horvath E; Smyth HS
    Virchows Arch A Pathol Anat Histopathol; 1993; 422(3):193-201. PubMed ID: 8493775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroendocrine tumors secreting growth hormone-releasing hormone: Pathophysiological and clinical aspects.
    Gola M; Doga M; Bonadonna S; Mazziotti G; Vescovi PP; Giustina A
    Pituitary; 2006; 9(3):221-9. PubMed ID: 17036195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A clinicomorphological study of pituitary tumors associated with the clinical syndrome of acromegaly.
    Andreeva M; Georgiev T; Bosadjieva E; Karagiosov L; Karagiosov K; Tomova A; Matrosov P; Kirilov G; Diankov L; Christova T
    Exp Clin Endocrinol; 1991; 98(3):223-7. PubMed ID: 1778242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acromegaly and somatotroph hyperplasia with adenomatous transformation due to pituitary metastasis of a growth hormone-releasing hormone-secreting pulmonary endocrine carcinoma.
    Nasr C; Mason A; Mayberg M; Staugaitis SM; Asa SL
    J Clin Endocrinol Metab; 2006 Dec; 91(12):4776-80. PubMed ID: 16968791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multilineage Pituitary Neuroendocrine Tumors (PitNETs) Expressing PIT1 and SF1.
    Asa SL; Mete O; Riddle ND; Perry A
    Endocr Pathol; 2023 Sep; 34(3):273-278. PubMed ID: 37268858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mammosomatotroph and mixed somatotroph-lactotroph adenoma in acromegaly: a retrospective study with long-term follow-up.
    Lv L; Jiang Y; Yin S; Hu Y; Chen C; Ma W; Jiang S; Zhou P
    Endocrine; 2019 Nov; 66(2):310-318. PubMed ID: 31368083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Production of alpha-subunit of glycoprotein hormones by pituitary somatotroph adenomas in vitro.
    Kontogeorgos G; Asa SL; Kovacs K; Smyth HS; Singer W
    Acta Endocrinol (Copenh); 1993 Dec; 129(6):565-72. PubMed ID: 7509101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of growth hormone-releasing hormone (GHRH) on densely granulated somatotroph adenomas and sparsely granulated somatotroph adenomas in vitro: a morphological and functional investigation.
    Kawakita S; Asa SL; Kovacs K
    J Endocrinol Invest; 1989; 12(7):443-48. PubMed ID: 2551950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokeratin 8/18-negative somatotroph pituitary neuroendocrine tumours (PitNETs, adenomas) show variable morphological features and do not represent a clinicopathologically distinct entity.
    Soukup J; Cesak T; Hornychova H; Manethova M; Michnova L; Netuka D; Vitovcova B; Cap J; Ryska A; Gabalec F
    Histopathology; 2021 Sep; 79(3):406-415. PubMed ID: 33738859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth hormone-releasing hormone-producing tumors: clinical, biochemical, and morphological manifestations.
    Sano T; Asa SL; Kovacs K
    Endocr Rev; 1988 Aug; 9(3):357-73. PubMed ID: 3145190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Silent somatotroph tumour revisited from a study of 80 patients with and without acromegaly and a review of the literature.
    Chinezu L; Vasiljevic A; Trouillas J; Lapoirie M; Jouanneau E; Raverot G
    Eur J Endocrinol; 2017 Feb; 176(2):195-201. PubMed ID: 27913611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolactin and Growth Hormone Signaling and Interlink Focused on the Mammosomatotroph Paradigm: A Comprehensive Review of the Literature.
    Araujo-Castro M; Marazuela M; Puig-Domingo M; Biagetti B
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathologic Characteristics of Somatotroph Pituitary Tumors-An Observational Single-Center Study.
    Tomasik A; Stelmachowska-Banaś M; Maksymowicz M; Czajka-Oraniec I; Raczkiewicz D; Zieliński G; Kunicki J; Zgliczyński W
    Biomedicines; 2023 Dec; 11(12):. PubMed ID: 38137536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of the growth hormone response to vasoactive intestinal peptide and gonadotropin-releasing hormone in acromegaly.
    Watanobe H; Tamura T
    Neuropeptides; 1995 Feb; 28(2):115-24. PubMed ID: 7746355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.